Medicines360 Applauds U.S. Congress for Enshrining Nonprofit Pharma in Federal Law for the First Time

The Omnibus Legislation Passed Last Week Includes Provisions to Conduct a GAO Report on Nonprofit Pharma and include Nonprofit Pharma in an HHS Domestic Manufacturing Study 

January 4, 2023 

San Francisco, CA – Last week, Congress passed bipartisan legislation to fund the Federal Government for the remainder of Fiscal Year 2023 and to ensure other pivotal priorities were completed before the end of the 117th Congress. Included among those must-move priorities: the nonprofit pharmaceutical industry was introduced for the first time ever in Federal law. 

Statement from Tina Raine-Bennett, MD, MPH, CEO at Medicines360  

At Medicines360, we have always known that the nonprofit pharmaceutical industry would be a critical driver toward providing equitable access to medicines and devices in the United States. Today, we applaud the bipartisan lawmakers in the United States Congress who moved to officially include that future in Federal law. The inclusion of critical provisions in the end-of-year omnibus legislation concerning nonprofit pharma is an incredible victory for health equity in this country. This victory would not have been possible without the visionary leadership of Sen. Jacky Rosen (D-NV) who has been the leading voice calling for legislation supporting nonprofit pharma, and Sen. Mitt Romney (R-UT) who reached across the aisle to introduce a provision ultimately passed today; we thank them for their incredible commitment to improving the health and wellbeing of all people across the country. In the days ahead, we look forward to working with health care champions in the 118th Congress and the Biden-Harris Administration to continue this incredible momentum toward building the health care system our country deserves.” 

The omnibus legislation passed last week (H.R. 2617) directs the Government Accountability Office (GAO) to conduct a report on the impact that nonprofit drug companies would have on lowering drug costs, addressing drug shortages, and accelerating the development of new drugs. The report will also look at existing barriers to the success of nonprofit pharmaceutical organizations, and what Congress can do to support them. The omnibus legislation also includes a provision allowing the Health and Human Services Assistant Secretary for Planning and Evaluation to include nonprofit pharmaceutical companies in a study on domestic manufacturing. 

An astounding four pieces of legislation considered in the 117th Congress included provisions supporting the nonprofit pharmaceutical industry. Sen. Rosen has been a leading champion for the nonprofit pharmaceutical model and the driver of this congressional momentum. In 2021, Sen. Rosen introduced the first piece of legislation naming nonprofit pharma: the Expanding Access to Affordable Prescription Drugs and Medical Devices Act (S.2257), which would improve the ability of nonprofit pharmaceutical organizations to sustainably provide affordable medicines to U.S. patients in a number of ways. In 2022, Sen. Rosen was joined by Sen. Romney to introduce S.4341, standalone legislation calling for the same GAO report ultimately included in this final omnibus. Thanks to the incredible leadership of Sen. Rosen, Sen. Romney, and the other health care champions of the 117th Congress, the nonprofit pharmaceutical industry is a critical step closer to fulfilling its promise to improve the cost of prescription drugs and devices.   

About Medicines360  

Medicines360, located in San Francisco, California, is a global nonprofit women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. For more information, visit  

About Medicines360

Located in San Francisco, California, Medicines360 is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and public sector engagement. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments while ensuring more women worldwide can access the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.